Atopic Dermatitis

Patients treated with the monoclonal antibody had increased incidences of conjunctivitis, though many of these incidences were considered mild and were resolved by the end of the study.

Investigators recommended a treatment course of at least 1-2 months with medium strength to potent topical corticosteroids should be considered before dupilumab discontinuation in affected children and adolescents.

In this episode of DermView, Adelaide Hebert, MD, explains the clinical manifestations of eczema, how the chronic the condition is, and the benefits of using ceramide cream for management.

FDA approval of ruxolitinib (Opzelura, Incyte) adds the first new topical anti-inflammatory to the atopic dermatitis (AD) armamentarium in 50 years, but boxed warnings raise questions.

People are born with sterile skin and then gain microbiota throughout their life. Lawrence J. Green, MD, FAAD, explains how this affects the skin barrier and ultimately plays a role in atopic dermatitis at the 2021 Fall Clinical Dermatology Conference.

LEO Pharma releases the 16-week data regarding tralokinumab (Adtralza; LEO Pharma) as a treatment for adolescent patients aged 12 to 17 years.

Neal Bhatia, MD, explores steroid alternatives in his presentation at the Fall Clinical Dermatology Conference.

In this week’s Pointers with Dr Portela, the 208SkinDoc explains what keratosis pilaris is and whether or not it can be cured.

In this episode of DermView, Adelaide Hebert, MD, explains how eczema can lead to growth issues in pediatric patients, how environmental factors may play a role in flare ups, and more.

In this exclusive video interview with Dermatology Times®, Andrew Blauvelt, MD, MBA, discusses the newest phase 3 clinical data on investigational tralokinumab as a potential treatment option in atopic dermatitis.

Amgen and Kyowa Kirin announce positive study data from their phase 2 trial of AMG 451/KHK4083.

Nemolizumab phase 2 clinical trial data for patients with prurigo nodularis and atopic dermatitis was recently released at the EADV.

How are atopic dermatitis and out of pocket health care expenses related? This study aimed to find out.

A recent study in JAMA Dermatology investigated the possible association of atopic dermatitis and mental health outcomes across childhood.

In this episode, Marc Serota, MD, discusses his research regarding type 2 inflammation, the future of treating it as 1 condition or 2, and more!

Delgocitinib is the first and only topical JAK/STAT pathway inhibitor in Japan, and recent data suggests it is effective in the management of atopic dermatitis.

Two poster presentations at the EADV 30th annual conference showed the efficacy of roflumilast foam for nonsteroidal treatment of psoriasis or seborrheic dermatitis.

Patients with mild to moderate AD have a new topical treatment option, but physicians will need to prepare for some focused conversations about safety.

At Maui Derm NP+PA Fall 2021, Vikash S. Oza, MD, and Matthew J. Zirwas, MD, discuss the current Rx and Dx of atopic dermatitis in children.

New therapies raise patient expectations for fast efficacy, lower costs, and fewer adverse effects.

Investigators added that the meaning of each laboratory marker is dependent on the drug that is being used for treatment.

NEA’s Eczema Expo highlights new drugs, steroid withdrawal, alternative therapies.

Incyte announced the FDA has approved its topical selective Janus kinase (JAK)1/JAK2 inhibitor ruxolitinib (Opzelura) for the treatment of mild to moderate atopic dermatitis.

Verrica Pharmaceuticals has received a complete response letter from the FDA identifying deficiencies at a manufacturing facility for VP-102.

Derm-Biome’s topical compounds have positive results in preclinical trial.

Dermavant has announced it has dosed the first patient in its phase 3 trial evaluating tapinarof cream for the treatment of moderate to severe atopic dermatitis.

A recent phase 3 trial investigated the safety of dupilumab as a treatment for severe atopic dermatitis in pediatric patients ages 6 to 11 years.

A new study sheds light on some of the atopic disease risks that are associated with early childhood and continue into midlife.

Mark Lebwohl, MD, takes a deep dive in the recent delay in approval for multiple JAK inhibitor drugs for treatment of inflammatory skin conditions such as psoriasis and atopic dermatitis. He also discusses the impact of the delay, as well as the benefits of JAK inhibitors for inflammatory skin diseases, and an outlook for the future of this drug class.

The FDA is now requiring black box warning for certain JAK inhibitors used to treat arthritis. This news comes amid delay in FDA approval for multiple JAK inhibitors for the treatment of inflammatory skin conditions.